oa SA Pharmaceutical Journal - Januvia®: sitagliptin for type 2 diabetes : drug info : new product focus

Volume 80, Issue 1
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Sitagliptin monotherapy, or as add-on therapy, is generally well tolerated with the additional benefit of causing weight loss in patients with type 2 diabetes. Sitagliptin also has a lower potential for hypoglycaemic events because of the glucose-dependent mechanism of action.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error